COST-EFFECTIVENESS OF BOCEPREVIR THERAPY IN ADULT PATIENTS WITH CHRONIC HEPATITIS C (HCV) GENOTYPE 1

被引：1
|
作者：
Mernagh, P. [1 ]
Feng, J. [1 ]
Del Cuore, M. [2 ]
机构：
[1] Optum, Sydney, NSW, Australia
[2] Merck Sharp & Dohme Australia, Sydney, NSW, Australia
来源：
VALUE IN HEALTH | 2013年 / 16卷 / 03期
关键词：
D O I：
10.1016/j.jval.2013.03.440
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
引用
收藏
页码：A94 / A94
页数：1
相关论文
共 50 条
  • [41] Cost-effectiveness of hepatitis A vaccination in patients with chronic hepatitis C - Reply
    Myers, RP
    Gregor, JC
    Marotta, PJ
    [J]. HEPATOLOGY, 2000, 32 (04) : 874 - 875
  • [42] COST-EFFECTIVENESS OF TELAPREVIR IN GENOTYPE 1 CHRONIC HEPATITIS-C VIRUS INFECTION IN VENEZUELA
    Garcia Marti, S.
    Alcaraz, A.
    Valanzasca, P.
    Garay, O. U.
    McMullen, M.
    Rey Ares, L.
    Obando, C. A.
    Caporale, J.
    [J]. VALUE IN HEALTH, 2013, 16 (07) : A714 - A714
  • [43] COST-EFFECTIVENESS OF LEDIPASVIR/SOFOSBUVIR FOR THE TREATMENT OF GENOTYPE 1 OR 4 CHRONIC HEPATITIS C IN SCOTLAND
    Dillon, J.
    Treharne, C.
    Howells, R.
    [J]. JOURNAL OF HEPATOLOGY, 2015, 62 : S635 - S635
  • [44] The cost-effectiveness of vaccinating chronic hepatitis C patients against hepatitis
    Jacobs, RJ
    Koff, RS
    Meyerhoff, AS
    [J]. AMERICAN JOURNAL OF GASTROENTEROLOGY, 2002, 97 (02): : 427 - 434
  • [45] Treatment of chronic hepatitis C genotype 1 with triple therapy comprising telaprevir or boceprevir
    Moradpour, Darius
    Muellhaupt, Beat
    [J]. SWISS MEDICAL WEEKLY, 2012, 142
  • [46] Cost-effectiveness analysis of glecaprevir/pibrentasvir regimen for treating Chinese patients with chronic hepatitis C genotype 1 and genotype 2 infection
    Zhou, Hui-Jun
    Wu, Gang
    Li, Ji-Ming
    Naidoo, Nasheen
    Xie, Yan-Xiang
    Feng, Bo-Lan
    Wang, Pei
    Luo, Ji-Wei
    [J]. ANNALS OF PALLIATIVE MEDICINE, 2021, 10 (10) : 10313 - 10326
  • [47] The accuracy and cost-effectiveness of hepatitis C core antigen assay in the monitoring of anti-viral therapy in patients with chronic hepatitis C genotype 4
    Kamal, S. M.
    Kassim, S.
    EL Gohary, E.
    Fouad, A.
    Nabegh, L.
    Hafez, T.
    Bahnasy, K.
    Hassan, H.
    Ghoraba, D.
    [J]. ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2015, 42 (03) : 307 - 318
  • [48] EFFECTIVENESS AND COST-EFFECTIVENESS OF TRIPLE THERAPY WITH TELAPREVIR AND BOCEPREVIR FOR CHRONIC HEPATITIS C: A DECISION ANALYSIS FROM THE PERSPECTIVE OF THE BRAZILIAN PUBLIC HEALTH SYSTEM
    Borba, H. H.
    Rochau, U.
    Wiens, A.
    Sroczynski, G.
    Siebert, U.
    Pontarolo, R.
    [J]. VALUE IN HEALTH, 2017, 20 (09) : A883 - A883
  • [49] Management of treatment-naive chronic hepatitis C genotype 1 patients: a cost-effectiveness analysis of treatment options
    Cortesi, P. A.
    Ciaccio, A.
    Rota, M.
    Lim, J. K.
    De Salvia, S.
    Okolicsanyi, S.
    Vinci, M.
    Belli, L. S.
    Mantovani, L. G.
    Strazzabosco, M.
    [J]. JOURNAL OF VIRAL HEPATITIS, 2015, 22 (02) : 175 - 183
  • [50] Cost-effectiveness analysis of sofosbuvir-simeprevir regimens for chronic hepatitis C genotype 1 patients with advanced fibrosis
    Mar, Javier
    Mar-Barrutia, Lorea
    Gimeno-Ballester, Vicente
    San Miguel, Ramon
    [J]. MEDICINA CLINICA, 2016, 146 (02): : 61 - 64
12345